Want to see CNTX full AI Analyst Report?
Ct-202
Colorectal Cancer, Urothelial Cancer, Triple Negative Breast Cancer (Tnbc)
Phase I
Not Yet Recruiting
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Apr 16, 2026
―
Ct-95
Epithelial Ovarian Cancer, Colorectal Cancer, Cholangiocarcinoma Non-Resectable, Mesothelin-Expressing Tumors, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced Or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Mesothelin-Expressing Advanced Cancers, Mesothelin-Positive Advanced Malignant Solid Tumors
Phase I
Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Dec 18, 2024
Elacestrant, Onapristone
Breast Cancer
Phase I/II
Withdrawn
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
May 30, 2023
―
Elacestrant, Onapristone
Breast Cancer
Phase I/II
Terminated
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Nov 03, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Context Therapeutics (CNTX) have in its pipeline
CNTX is currently developing the following drugs: Ct-202, Ct-95, Ctim-76. These drug candidates are in various stages of clinical development as the company works toward FDA approval.